Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.The heralded model United Kingdom experts have largely used to guide their coronavirus policies is “totally unreliable,” according to experts. The criticisms follow a series of policy turnabouts, including Prime Minister Boris Johnson’s decision to extend the national lockdown. The United…
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.Although a judge denied Lori Loughlin and Mossimo Giannulli’s request to have their college admissions scandal case dismissed, he nonetheless noted that the allegations they made against the prosecution are “troubling” and “disturbing.”In court documents previously obtained by Fox…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f